Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label, Dose Escalation and Expansion Study of STX-0712 in Patients With Advanced Hematologic Malignancies

NCT06950034 is registered in ClinicalTrials.gov with Solu Therapeutics, Inc as lead sponsor.

NCT NCT06950034
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06950034 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label, Dose Escalation and Expansion Study of STX-0712 in Patients With Advanced Hematologic Malignancies
Lead sponsor
Solu Therapeutics, Inc
Phase
Phase 1
Overall status
Recruiting
Start date
March 13, 2025
Completion date
June 30, 2027
Enrollment
105 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

acute monocytic leukemia, acute myeloid leukemia, acute myeloid leukemia (aml), acute myeloid leukemia post cytotoxic therapy, acute myeloid leukemias, chronic myelomonocytic leukemia, chronic myelomonocytic leukemia (cmml), chronic myelomonocytic leukemia-1, chronic myelomonocytic leukemia-2, cmml, refractory acute myeloid leukemia (aml), refractory chronic myelomonocytic leukemia